Chemotherapy cardiotoxicity attenuation – European Clinical Trials Information Network

Early detection of heart damage using cardiac magnetic resonance imaging in cancer patients receiving doxorubicin, epirubicin, pixantrone and other anthracyclines

Wed, 29 Apr 2026 15:07:29 +0000

This clinical trial focuses on patients receiving anthracycline-based cancer therapy. Anthracyclines are powerful cancer medications that include doxorubicin, epirubicin, pixantrone, idarubicin, daunorubicin, and mitoxantrone. These medications are given through an intravenous line as part of standard cancer treatment.

The study aims to determine if cardiac magnetic resonance imaging (CMR) can detect early heart damage in patients receiving anthracycline treatment. During CMR scans, a special substance called contrast agent is used to make certain parts of the heart more visible in the images.

Throughout the treatment period, which may last up to 8 months, participants will undergo several CMR scans and blood tests. The study will look for changes in heart tissue and measure certain substances in the blood that might indicate heart damage. Participants will also receive regular heart ultrasound tests called echocardiograms to monitor their heart function during treatment.

Study on Dapagliflozin to Reduce Heart Damage from Chemotherapy in Breast Cancer Patients

Wed, 29 Apr 2026 15:02:29 +0000

This clinical trial is focused on studying the effects of a medication called dapagliflozin on heart health in patients with breast cancer who are receiving certain types of chemotherapy. The chemotherapy treatments being studied include those based on anthracycline, with or without the addition of trastuzumab. These treatments can sometimes lead to heart problems, known as chemotherapy-induced cardiotoxicity, which is the main concern of this study.

The purpose of the study is to see if taking dapagliflozin can help reduce the risk of developing heart issues during and after chemotherapy. Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo. The study will last for 18 months, during which time participants will be monitored for any signs of heart problems, both those that cause symptoms and those that do not.

This trial is being conducted to explore the potential protective role of SGLT-2 inhibitors, a class of medications that includes dapagliflozin, in preventing heart damage caused by chemotherapy. The study aims to provide valuable insights into whether this medication can help maintain heart health in patients undergoing treatment for breast cancer.

Study on Empagliflozin to Prevent Heart Damage in Cancer Patients Receiving Anthracycline Chemotherapy

Wed, 29 Apr 2026 15:01:20 +0000

This clinical trial is focused on studying the prevention of heart damage, known as cardiotoxicity, in patients with cancer who are undergoing chemotherapy treatments that include high doses of drugs called anthracyclines. These drugs, such as doxorubicin and epirubicin, are commonly used in cancer treatment but can sometimes affect the heart. The study will use a medication called empagliflozin, which is being tested to see if it can help protect the heart during these treatments.

The purpose of the study is to evaluate how effective and safe empagliflozin is in preventing heart problems in cancer patients receiving these chemotherapy drugs. Participants in the study will be randomly assigned to receive either empagliflozin or a placebo, which looks like the medication but does not contain any active ingredients. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results.

Throughout the study, participants will take the medication or placebo orally in the form of film-coated tablets. The study will monitor the participants over a period of time to observe any changes in heart function and to check for any side effects. The main focus will be on whether empagliflozin can prevent a decrease in the heart’s ability to pump blood effectively, which is a common issue with high doses of anthracyclines. The study aims to provide valuable information on whether this medication can be a helpful addition to cancer treatment plans to protect heart health.